Abstract: The present invention relates to lipopeptide-based compounds for use in the diagnosis, prevention and/or treatment of a liver disease or condition, preferably liver involved metabolic diseases, as well as in the control or modification of the cholesterol level or cholesterol uptake and, thus, diagnosis, prevention and/or treatment of a cardiovascular disease. The present invention furthermore relates to an in vitro or in vivo assay or method for testing or measuring the NTCP-mediated transport of test compound(s). The present invention furthermore relates to a method for the diagnosis, prevention and/or treatment of a liver disease or condition, comprising administering a therapeutically effective amount of a lipopeptide-based compound to a patient. The present invention furthermore relates to a method for the diagnosis, prevention and/or treatment of a cardiovascular disease.

Abstract: Inter-alia, an implantable lens is disclosed comprising a refractive element causing chromatic aberration and an element inducing an increase of the chromatic aberration. It is further disclosed a method for producing an implantable lens.

Abstract: The present invention relates to an effector polypeptide comprising (i) an amino acid sequence at least 70% identical to the amino acid sequence RSNLGWLCLLLLPIPLIVWVKRK (SEQ ID NO: 1); and (ii) an exchange of an amino acid to a non-identical amino acid at least one position selected from the list consisting of positions 1, 2, 3, 19, 22, and 23 of the amino acid sequence of (i). The present invention also relates to a polynucleotide comprising a nucleic acid sequence encoding the aforesaid effector polypeptide. and to related host cells. pharmaceutical compositions. and uses. and to related uses in medicine, in particular in treating and/or preventing cancer, inflammatory disease, or acute or chronic neurodegenerative disease.

Abstract: The present invention relates to a compound of formula (1) or a pharmaceutically acceptable salt or solvate thereof, wherein Y3 is O or S, wherein s, t, u and w are, independently of each other, 0 or 1, wherein i is an integer of from 1 to 3, wherein j is an integer of from 3 to 5, and wherein Z1, Z2 and Z3 are independently of each other, selected from the group consisting of CO2H, —SO2H, —SO3H, —OSO3H, and —OPO3H2, R1 is —CH3 or H, preferably H, X is selected from the group consisting of alkylaryl, aryl, alkylheteroaryl and heteroaryl, Y1 and Y2 are independently, of each other, selected from the group consisting of aryl, alkylaryl, cycloalkyl, heterocycloalkyl, heteroaryl and alkylheteroaryl, and wherein A is a chelator residue having a structure selected from the group consisting of (Ia), (Ib) and (Ic) wherein R2, R3, R4 and R5 are, independently of each other, selected from the group consisting of H, —CH2—COOH and —CH2—C(?O)—NH2 or wherein R2 and R4 form a —(CH2)n— bridge with n being an integer

Abstract: The present invention relates to xenon gas for use in in vivo methods of sensitizing glioma cells in a subject for radiation therapy, as well as related in vitro methods.

Abstract: The invention relates to a process for the preparation of acetals from carbon dioxide. The invention also relates to a mixture of phosphorus containing ligands comprising least one polydentate ligand and at least one monodentate ligand. Further, the invention also relates to the use of mixtures comprising at least one polydentate ligand and at least one monodentate ligand in transition metal complexes for the preparation of acetals.

Abstract: The present invention relates to a perivascular implant comprising (i) a housing comprising a receptacle for an effector matrix, and (ii) a fastening element adapted for at least partially embracing a tubular bodily structure, wherein said housing, said receptacle for an effector matrix, and said fastening element are arranged such that after implantation of the device the receptacle for an effector matrix at least partially is in contact with said tubular bodily structure and/or a vasculature originating from said tubular bodily structure, and to uses, methods, and kit related thereto.

Abstract: The present invention relates to an endograft device (101) for treatment of ruptures (104.9) in one or more inner layers of a blood vessel (104), in particular, an aorta, comprising an anchoring unit (101.1) and a sleeve unit (101.2). The endograft device (101) defines an upstream endograft end (101.3) and a downstream endograft end (101.4), upstream and downstream being defined, in an implanted state of the endograft device (101), in relation to a general natural blood flow defining a blood flow direction within the blood vessel (104). The anchoring unit (101.1) is a collapsible unit located at the upstream endograft end (101.3), wherein the anchoring unit (101.1) is configured to anchor, in the implanted state, the endograft device (101) within the blood vessel (104) by engaging an inner surface of the blood vessel (104) with an expanded anchoring section (101.5). The sleeve unit (101.2) is located downstream of the anchoring unit (101.1), wherein the sleeve unit (101.

Abstract: The present invention relates to agents for use in the treatment of glioma, in particular astrocytoma WHO II° and III°, as well as IV° (glioblastoma), in a subject.

Abstract: A compound of general formula I Also, the use of the compound for the complexation of a metal ion, including lutetium ions or actinium ions, and the method for the complexation of a metal ion in which the compound is contacted with the metal ion at a reaction temperature in the range of from 20 to 50° C.

Abstract: The present invention relates to agents for use in the treatment of glioma, in particular astrocytoma WHO II° and III°, as well as IV° (glioblastoma), in a subject.

Abstract: The present invention concerns a pharmaceutical composition where a checkpoint inhibitor is combined with an oncolytic virus and the use of said combination for the treatment of cancer.

Abstract: The present invention relates to a polypeptide and a nucleic acid encoding the polypeptide for use in a method of detecting the presence of hepatitis D virus (HDV) and/or of diagnosing an HDV infection and/or of monitoring the treatment of an HDV infection. The present invention further relates to an in vitro method, an immunographic test device as well as a kit. In particular, the present invention relates to a point of care diagnostic for HDV infections.

Abstract: A computer-implemented method for testing ocular drug delivery is provided. The ocular drug delivery is characterized by a set of delivery parameters comprising at least one of drug type, drug concentration, drug amount, injection position, penetration depth. The method comprises: providing a model for the human eye, wherein the model comprises: a geometry equation defining a three-dimensional generalized limacon for the geometry of the vitreous body, geometry equations describing all components of the eye; and a set of equations defining a drug convection in the vitreous body; setting a target drug state in the vitreous body; using the model to perform at least one simulation of the ocular drug delivery with a given set of values for the set of delivery parameters, wherein the at least one simulation provides a simulated drug state in the vitreous body; comparing the target drug state and the simulated drug state.

Abstract: A body fluid leakage detection aqueous composition, for use e.g. in intraoperative pancreatic fluid leakage detection. The composition comprises a gelling agent, increasing the viscosity of the composition, and buffering species, the composition thereby being buffered. The gelling agent is cross-linked ?-glucan microspheres. Further, the composition comprises a pH-indicator. The pH of the composition is at least 0.1 pH units lower, or higher, than a pKa of the pH-indicator.

Abstract: The invention relates to oral pharmaceutical compositions of an active agent and a lipid conjugate of a cell penetrating peptide conjugated to a lipid molecule. The conjugated lipid acts as a permeation enhancer for the active agent in the composition. In other words, oral bioavailability of the active agent increases when co-administered together with the lipid conjugate described herein.

Abstract: The invention relates to the use of a recombinant porcine adeno-associated virus (AAV) vector comprising a peptide-modified porcine AAV serotype 1 (AAVpol) capsid in gene therapy of muscle and/or central nervous system (CNS) disorders, in particular neuromuscular diseases such as genetic neuromuscular diseases.

Abstract: The present invention relates to a polynucleotide comprising a Nuclear factor of activated T-cells (NFAT) binding site sequence and a reverse complement of said NFAT binding site sequence separated by a spacer sequence, to said polynucleotide for use in treating and/or preventing disease, and to viral particles, compositions, and uses related thereto. The present invention further relates to a polynucleotide comprising a Nuclear factor of activated T-cells (NFAT) binding site sequence and a reverse complement of said NFAT binding site sequence for use in treating and/or preventing an NFAT-mediated disease.

Abstract: The present invention relates to a recombinant virus of the family Paramyxoviridae comprising an expressible polynucleotide encoding at least one of (i) a tumor antigen, (ii) a fragment of a tumor antigen, and (iii) a variant of (i) or (ii). The present invention further relates to a polynucleotide encoding said recombinant virus of the family Paramyxoviridae and to a host cell comprising said recombinant virus of the family Paramyxoviridae and/or said polynucleotide encoding said recombinant virus of the family Paramyxoviridae. Moreover, the present invention relates to a method for activating immune cells with antitumor activity in a sample comprising cancer cells and to further means, methods, and uses related to the present invention.

Abstract: The present invention relates to pharmaceutical compositions with isolated and treated whole blood cells or Peripheral Blood Mononuclear Cells (PBMCs) as well as such pharmaceutical compositions for use in the prevention and/or treatment of organ or cell graft rejection in a human graft recipient.